We're making a difference. Nearly 3,000 of our GeneXpert® Systems are revolutionizing diagnostics around the world. Automated molecular testing is redefining efficiency by strengthening simplicity, accuracy and output. From preparation to reporting, process steps are shrinking by 56% and turnaround times by at least 20 hours because of Xpert® MRSA alone. Together, we’re accelerating progress for patients and practitioners everywhere. Fast forwarding changes what’s next.

Knowledge is prevention. Our Xpert® SA Nasal Complete is helping physicians drastically decrease life-threatening complications by identifying carriers of Staphylococcus aureus with a quick pre-surgical screening. Same-day confirmation allows proactive decolonization, reducing the chance of post-operative infection. Anticipating risk changes what’s predictable.

It's called the emergency room for a reason. Patients in trauma must be assessed for hazardous contagions as rapidly as they’re admitted. Our Xpert® MRSA/SA SSTI (Skin and Soft Tissue) keeps pace by swiftly revealing the exact nature of suspicious wounds. Doctors can skip the sweep of broad-spectrum antibiotics and premature isolation in favor of targeted therapies and focused safety measures. Zeroing in changes what’s seen.

Safeguarding newborns shouldn’t stop short. Yet, fully preventable Group B Streptococcus remains a leading cause of death and serious infection in infants. Moms-to-be are typically checked for the bacteria at 35–37 weeks, but can often develop it later in pregnancy. Our Xpert® GBS returns positive results in about an hour, elevating the standard of care with an on-the-spot screening at delivery. Transcending expectations changes what’s common.

It's one thing to speed up a lab. It’s another to get answers where they matter most. Our Xpert® MTB/RIF is so easy to use, caregivers on the front lines of the developing world can diagnose the most resistant cases of tuberculosis in ninety minutes instead of six weeks. In the US, that abbreviation means saving time. In villages with treatment-detouring healthcare shortages, it means saving lives. Especially for the high percentage of patients co-infected with HIV. Reaching further changes what’s possible.

We’re just getting started. Our suite of 12 FDA-cleared tests is making unprecedented headway across the globe in the fight against infectious disease. But our commitment to the evolution of patient care is only beginning. With new diagnostics expected in oncology, genetics and women’s health, we’re aiming to affect outcomes in every department of every hospital. And everywhere else we can help people with information that’s clear, fast and true. Leaping ahead changes what’s done.